Study Published in JAMA Finds Hospital Availability of TCAR Associated with an Improvement in Overall Outcomes for Carotid Revascularization
The study found the availability of TCAR at a hospital was associated with a significant decrease in the likelihood of major adverse cardiovascular events (MACE), a composite of in-hospital stroke, myocardial infarction, or death at 30 days after carotid revascularization, whether TCAR or carotid endarterectomy (CEA).
- The study found the availability of TCAR at a hospital was associated with a significant decrease in the likelihood of major adverse cardiovascular events (MACE), a composite of in-hospital stroke, myocardial infarction, or death at 30 days after carotid revascularization, whether TCAR or carotid endarterectomy (CEA).
- We believe this indicates that centers that offer TCAR are able to better align patients with the best procedure for their individual clinical and anatomic characteristics.
- The ENROUTE Transcarotid Stent is intended to be used in conjunction with the ENROUTE Transcarotid Neuroprotection System (NPS) during the TCAR procedure.
- The companys flagship procedure, TransCarotid Artery Revascularization (TCAR), is clinically proven to treat blockages in the carotid artery at risk of causing a stroke.